|

The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome

RECRUITINGSponsored by University Medical Centre Ljubljana
Actively Recruiting
SponsorUniversity Medical Centre Ljubljana
Started2021-09-06
Est. completion2026-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Minimum age 18 years
* Established TTS per InterTak registry criteria
* Signed consent form

Exclusion Criteria:

* Patients under the age of 18 years
* Ischemic heart disease with at least one complete total occlusion
* Other concurrent cardiomyopathies
* Active infectious myocarditis
* obstructive coronary artery disease
* Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event
* Previous interventional coronary artery procedure in the last 6 months before TTS acute event
* Significant valvular heart disease
* Significant peripheral artery occlusive disease
* Active or remitted hematologic malignancy
* Patients receiving immunosuppressive therapy
* Significant comorbiditeis affecting patients survival (malignancy)
* Failure to obtain freely given, informed consent form.

Conditions6

CD34+ Stem CellsCardiac Contractility RecoveryHeart DiseaseHeart FailureMicrovascular DysfunctionTako Tsubo Cardiomyopathy

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.